BALAXI vs BI: Stock Comparison

BALAXI PHARMACEUTICALS LIMITED vs Bilcare Ltd

Live data: 20 April 2026, 4:01 PM IST • Source: NSE and company filings

Bilcare Ltd is the larger company by market capitalisation. BALAXI PHARMACEUTICALS LIMITED shows lower leverage, a higher ROCE and a higher net margin, while Bilcare Ltd shows a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of BALAXI PHARMACEUTICALS LIMITED and Bilcare Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BALAXI is more favourable on 5 of 11 scored metrics and BI on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BI is the larger company
₹140 Cr vs ₹135 Cr
EPS
BALAXI has higher earnings per share
₹1.72 vs ₹0.73
Revenue Growth (TTM YoY)
BI has faster revenue growth
0% vs -25.76%
EPS Growth (TTM YoY)
BI has faster EPS growth
0% vs -58.44%
Qtr Sales Growth
BALAXI has stronger quarterly sales growth
7.8% vs -3.28%
Qtr Profit Growth
BI has stronger quarterly profit growth
301% vs -95.5%
ROE
BI has a higher ROE
1.66% vs 0.57%
ROCE
BALAXI has a higher ROCE
13% vs 5.56%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBALAXIBI
SectorHealthcare
IndustryPharmaceuticals

Price

MetricBALAXIBI
Live Price₹26.67₹59.27
Day Change1.14%-3.64%
Volume51,3343,990
52-Week High₹52.5₹75
52-Week Low₹15.2₹51.62
Distance from 52W High-49.2%-20.97%

Valuation

MetricBALAXIBI
Market Cap₹135 Cr₹140 Cr
P/E Ratio12.63x
P/B Ratio0x
EPS₹1.72₹0.73
Book Value₹41.98₹83.6
Dividend Yield0%0%

Growth

MetricBALAXIBI
Revenue Growth (TTM YoY)-25.76%0%
EPS Growth (TTM YoY)-58.44%0%
Qtr Sales Growth7.8%-3.28%
Qtr Profit Growth-95.5%301%

Profitability & Leverage

MetricBALAXIBI
ROE0.57%1.66%
ROCE13%5.56%
Net Margin0.52%-2.36%
Operating Margin3.4%6.06%
Debt to Equity0.22x3.15x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricBALAXIBI
Promoter Holding65.99%30.01%
FII Holding0% 1.74 pp0.04%
DII Holding2.56% 2.54 pp0%
Public Holding31.45% 0.79 pp69.94%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALAXI PHARMACEUTICALS LIMITED and Bilcare Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.